Miscellaneous Travelex Issuerco 2 Plc: Entry into supplemental trust deeds 16.04.2025 / 12:55 CET/CEST The issuer is solely responsible for the content of this announcement.

Miscellaneous Travelex Issuerco 2 Plc: Consent Solicitation for New Money Notes 16.04.2025 / 10:50 CET/CEST The issuer is solely responsible for the content of this announcement.

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT | ...

LEO is a purpose-designed solution built with Google Cloud for smarter, faster, and more efficient sustainability disclosure, developed in partnership with Boston Consulting Group ...

AGM/EGM/Personnel AMAG Austria Metall AG: Dividend of EUR 1.20 per share and changes to the Supervisory Board approved 15.04.2025 / 16:00 CET/CEST The issuer is solely responsible for the content of ...

The team of religious educators Wolfgang Weirer and Mevlida Mešanović organized joint teaching sessions involving Christian and Islamic educators. The project gave rise to 12 recommendations for ...

Alliance/Sustainability Lenzing AG / Lenzing and Speyer & Grund set new standards for optimized sustainable supply chains 14.04.2025 / 09:00 CET/CEST The issuer is solely responsible for the content ...

Market Launch Marinomed Biotech AG: Launch of new moisturizing Carragelose eye drops in Austria 10.04.2025 / 07:45 CET/CEST The issuer is solely responsible for the content of this announcement.

Binder Grösswang advised Blockpit in connection with a multimillion-euro investment by Elevator Ventures, the venture capital arm of Raiffeisen Bank International AG. The Elevator Ventures Team was ...

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT | ...

Infosys (NSE: INFY) (BSE: INFY) (NYSE: INFY), a global leader in next-generation digital services and consulting, today announced it is extending its strategic collaboration with AIB, a financial ...

Results from phase 2a trial in ALS patients were published in Muscle and Nerve. Statistically significant 58% to 64% slower ALSFRS-R progression rate in IPL344-treated patients compared to the matched ...